MENU
FMED
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

FMED stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
FMED
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for FMED with price predictions
Jun 22, 2026

Aroon Indicator for FMED shows an upward move is likely

FMED's Aroon Indicator triggered a bullish signal on June 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 124 similar instances where the Aroon Indicator showed a similar pattern. In of the 124 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on FMED as a result. In of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on June 09, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .

FMED moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on June 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 176 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Exact Sciences Corp (NASDAQ:EXAS), Align Technology (NASDAQ:ALGN).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 42.45B. The market cap for tickers in the group ranges from 551.36M to 982.77B. LLY holds the highest valuation in this group at 982.77B. The lowest valued company is PHR at 551.36M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 27%. For the same ETF, the average monthly price growth was 35%, and the average quarterly price growth was 538%. KYMR experienced the highest price growth at 16%, while LEGN experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was 18% and the average quarterly volume growth was 217%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 66
Price Growth Rating: 47
SMR Rating: 78
Profit Risk Rating: 84
Seasonality Score: 35 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com
Aroon Indicator for FMED shows an upward move is likely